

1 **Longitudinal proteomic profiling of dialysis patients with COVID-19 reveals**
2 **markers of severity and predictors of death**

3
4 Jack Gisby^{*1}, Candice L. Clarke^{*1,2}, Nicholas Medjeral-Thomas^{*1,2}, Talat H. Malik¹,
5 Artemis Papadaki¹, Paige M. Mortimer¹, Norzawani B. Buang¹, Shanice Lewis¹,
6 Marie Pereira¹, Frederic Toulza¹, Ester Fagnano¹, Marie-Anne Mawhin¹, Emma E.
7 Dutton¹, Lunnathaya Tapeng¹, Arianne C. Richard³, Paul D. W. Kirk^{4,5}, Jacques
8 Behmoaras¹, Eleanor Sandhu^{1,2}, Stephen P. McAdoon^{1,2}, Maria F. Prendecki^{1,2},
9 Matthew C. Pickering¹, Marina Botto¹, Michelle Willicombe^{*1,2}, David C. Thomas^{*1,2},
10 James E. Peters^{*1,6}

11 * equal contributions

12
13 **Author Affiliations**

14 1) Centre for Inflammatory Disease, Dept of Immunology and Inflammation, Imperial College
15 London.

16 2) Renal and Transplant Centre, Hammersmith Hospital, Imperial College Healthcare NHS
17 Trust, London, United Kingdom.

18 3) CRUK Cambridge Institute and Cambridge Institute for Medical Research, University of
19 Cambridge.

20 4) MRC Biostatistics Unit, Forvie Way, University of Cambridge.

21 5) Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of
22 Cambridge.

23 6) Health Data Research UK, London, UK.

24
25 Correspondence to: James E. Peters. Email: j.peters@imperial.ac.uk
26

27 **Abstract**

28 End-stage kidney disease (ESKD) patients are at high risk of severe COVID-19. We
29 measured 436 circulating proteins in serial blood samples from hospitalised and non-
30 hospitalised ESKD patients with COVID-19 (n=256 samples from 55 patients). Comparison
31 to 51 non-infected patients revealed 221 differentially expressed proteins, with consistent
32 results in a separate subcohort of 46 COVID-19 patients. 203 proteins were associated with
33 clinical severity, including IL6, markers of monocyte recruitment (e.g. CCL2, CCL7),
34 neutrophil activation (e.g. proteinase-3) and epithelial injury (e.g. KRT19). Machine learning
35 identified predictors of severity including IL18BP, CTSD, GDF15, and KRT19. Survival
36 analysis with joint models revealed 69 predictors of death. Longitudinal modelling with linear
37 mixed models uncovered 32 proteins displaying different temporal profiles in severe versus
38 non-severe disease, including integrins and adhesion molecules. These data implicate
39 epithelial damage, innate immune activation, and leucocyte-endothelial interactions in the
40 pathology of severe COVID-19 and provide a resource for identifying drug targets.

41

42 **Introduction**

43 Coronavirus disease (COVID-19), caused by the SARS-CoV-2 virus, displays wide clinical
44 heterogeneity from asymptomatic to fatal disease. Patients with severe disease exhibit
45 marked inflammatory responses and immunopathology. The mechanisms underlying this
46 remain incompletely characterised and the key molecular mediators are yet to be
47 determined. The first treatment shown to reduce mortality from COVID-19 in randomised
48 trials was dexamethasone [1], a corticosteroid which has broad non-specific effects on the
49 immune system. Even with corticosteroid treatment, mortality in severe COVID-19 remains
50 significant. There is a wide armamentarium of existing drugs that target inflammation more
51 selectively, providing potential repurposing opportunities for the treatment of COVID-19.
52 Recently, the REMAP-CAP trial has demonstrated efficacy of anti-IL6 receptor blockade in
53 patients admitted to intensive care units with severe disease [2]. In order to select the most
54 promising agents for future trials, we urgently need to better understand the molecular
55 drivers of severe disease. Proteins are the effector molecules of biology and the targets of
56 most drugs. Therefore, proteomic profiling to identify the key mediators of severe disease
57 provides a valuable tool for identifying and prioritising potential drug targets [3].

58

59 Risk factors for severe or fatal COVID-19 include age, male sex, non-European ancestry,
60 obesity, diabetes mellitus, cardiovascular disease, and immunosuppression [4]. End-stage
61 kidney disease (ESKD) is one of the strongest risk factors for severe COVID-19 (estimated
62 hazard ratio for death 3.69) [4], and ESKD patients hospitalised with COVID-19 have a
63 mortality of approximately 30% [5–8]. ESKD patients have a high prevalence of vascular and

64 cardiometabolic disease (e.g. hypertension, ischaemic heart disease, diabetes), either as a
65 result of the underlying cause of their renal disease or as a consequence of renal failure. In
66 addition, ESKD results in both relative immunosuppression and chronic low-grade
67 inflammation, which may impact viral defence and the host inflammatory response.

68

69 Here we performed proteomic profiling of serial blood samples of ESKD patients with
70 COVID-19, leveraging the unique opportunity for longitudinal sampling in both the outpatient
71 and inpatient settings afforded by a large multi-ethnic haemodialysis cohort (**Figure 1a**).
72 These data revealed 221 proteins that are dysregulated in COVID-19 versus matched non-
73 infected ESKD patients. Using linear mixed models, joint models and machine learning, we
74 identified proteins that are markers of COVID-19 severity and risk of death. Finally, we
75 characterised the temporal dynamics of the blood proteomic response during COVID-19
76 infection in ESKD patients, uncovering 32 proteins that display altered trajectories in patients
77 with severe versus non-severe disease.

78

79 **Results**

80 We recruited 55 ESKD patients with COVID-19 (subcohort A; **Table 1**). All patients were
81 receiving haemodialysis prior to acquiring COVID-19. Blood samples were taken as soon as
82 feasible following COVID-19 diagnosis. At time of initial sample, 30 patients were outpatients
83 attending haemodialysis sessions and 25 were hospitalised inpatients (**Methods, Figure 1**).
84 Following the initial blood sample, serial sampling was performed for 51/55 patients. We also
85 recruited 51 non-infected haemodialysis patients as ESKD controls, mirroring the age, sex
86 and ethnicity distribution of the COVID-19 cases (**Figure 1 figure supplement 1a-c**). We
87 used the Olink proteomics platform to measure 436 proteins (**Supplementary File 1a**) in
88 256 plasma samples from the COVID-19 patients and the 51 control samples. The proteins
89 measured consisted of 5 multiplex 'panels' focussed on proteins relevant to immuno-
90 inflammation, cardiovascular and cardiometabolic disease. The 436 proteins assayed
91 showed strong enrichment for immune-related proteins (**Supplementary File 1b**).

92

93 In addition, we performed the Olink proteomic assays in 52 serum samples from a separate
94 set of 46 COVID-19 positive ESKD patients (subcohort B), and 11 serum samples from
95 ESKD COVID-19 negative controls (a subset of the controls described above). For the large
96 majority of patients only a single timepoint was available. A higher proportion of these
97 patients (41/46, 89%) were hospitalised and had severe disease (**Table 2**) than in subcohort
98 A (**Figure 1, Table 1**).

99

100 Proteomic differences between COVID-19 positive and negative ESKD patients

101 Principal components analysis (PCA) of proteomic data from subcohort A demonstrated
102 differences between samples from COVID-19 positive cases and controls, although the two
103 groups did not separate into discrete clusters (**Figure 2a-b**). To examine the effects of
104 COVID-19 on the plasma proteome, we performed a differential expression analysis in
105 subcohort A between COVID-19 cases (n=256 samples passing quality control from 55
106 patients) and non-infected ESKD controls (n=51) using linear mixed models, which account
107 for serial samples from the same individual (**Methods**). This revealed 221 proteins
108 associated with COVID-19 (5% false discovery rate, FDR); the vast majority were
109 upregulated, with only 40 downregulated (**Figure 3a, Supplementary File 1c**). In order to
110 provide a succinct and standardised nomenclature, we report proteins by the symbols of the
111 genes encoding them (see **Supplementary File 1a** for a mapping of symbols to full protein
112 names). The most strongly upregulated proteins (in terms of fold change) were DDX58,
113 CCL7, IL6, CXCL11, KRT19 and CXCL10, and the most strongly downregulated were
114 SERPINA5, CCL16, FABP2, PON3, ITGA11 and MMP12 (**Figure 3 figure supplement 1**).
115 Notably, many of the upregulated proteins were chemotaxins.

116

117 We observed that a high proportion of the measured proteins were associated with COVID-
118 19. Given the highly targeted nature of the Olink panels that we used (enriched for immune
119 and inflammation-related proteins), this was not surprising. Nevertheless, to ensure that the
120 Benjamini-Hochberg adjustment of p-values was controlling the false discovery rate at the
121 5% level, we performed two additional analyses (**Methods**). First, we estimated the FDR
122 using an alternative method (the plug-in method of Tibshirani [9]); this confirmed appropriate
123 FDR control. Second, we used permutation to estimate the distribution of the number of
124 proteins expected to be declared significant under the null hypothesis of no association
125 between any proteins and COVID-19. This showed that the probability of observing the
126 number of differentially abundant proteins we identified was highly unlikely under the null
127 (empirical $p < 1 \times 10^{-5}$; **Figure 3 figure supplement 2**).

128

129 Although our COVID-19 negative controls were well matched in terms of age, sex and
130 ethnicity (**Figure 1 figure supplement 1a-c**), perfect matching of comorbidities was not
131 feasible in the context of the healthcare emergency at the time of patient recruitment. There
132 was a higher prevalence of diabetes in the COVID-19 cases compared to the controls (61.8
133 % versus 47.1%, respectively; **Table 1**). To evaluate whether differing rates of diabetes had
134 impacted the proteins identified as differentially abundant between cases and controls, we
135 performed a sensitivity analysis adding diabetes as an additional covariate in the linear
136 mixed model. This did not materially affect our findings; estimated effect sizes and $-\log_{10}$ p-
137 values from models with and without the inclusion of diabetes were highly correlated

138 (Pearson $r > 0.99$, and $r = 0.95$, respectively; **Figure 3 figure supplement 3a-b**). Full results
139 from both models are shown in **Supplementary File 1c**. Similarly, there were also
140 differences in the underlying cause of ESKD in cases compared controls (**Table 1**). We
141 therefore performed a further sensitivity analysis adjusting for underlying cause of renal
142 failure. This did not make any meaningful difference to our results (**Figure 3 figure**
143 **supplement 3c-d, Supplementary File 1c**).

144

145 We also considered the possibility that timing of haemodialysis might affect the plasma
146 proteome. To minimise the impact of this, all samples were taken prior to haemodialysis. For
147 the large majority (86.6%) of samples, the most recent haemodialysis was between 48 and
148 72 hours prior to blood draw. This consistency in timing of blood sampling reduces the
149 potential for impact of this issue. Nevertheless, to evaluate whether timing of haemodialysis
150 might have impacted our results, we performed a sensitivity analysis including time from last
151 haemodialysis as a covariate. Our results were not materially affected by this, with $-\log_{10}$ p-
152 values and estimated effect sizes very highly correlated with those obtained without inclusion
153 of this covariate (Pearson $r > 0.99$ for effect size estimates and for $-\log_{10}$ p-values; **Figure 3**
154 **figure supplement 4a-b, Supplementary File 1c**).

155

156 We used the smaller subcohort B ($n=52$ serum samples from 46 patients with COVID-19;
157 **Methods**) for validation. We first projected the data from subcohort B into the PCA space of
158 subcohort A to examine how well the separation of cases and controls in the PCA space
159 replicated (**Methods**). This revealed clearer separation of infected and non-infected patients
160 than in subcohort A (**Figure 2c-d**), perhaps reflecting the higher proportion of hospitalised
161 patients (41 of 46 patients) in subcohort B (**Table 2**). We next performed differential
162 abundance analysis in subcohort B and found 201 proteins that were dysregulated in cases
163 versus controls (5% FDR) (**Supplementary File 1c**). Of the 221 differentially abundant
164 proteins from subcohort A, 150 (69.7%) were also identified in subcohort B at 5% FDR
165 (**Figure 4a**). Effect sizes in each dataset showed a strong correlation ($r=0.80$, **Figure 4b**).
166 This demonstrates that our findings are highly reproducible despite differences in sample
167 sizes and blood materials (plasma versus serum in subcohort A and B, respectively).

168

169 Proteins associated with COVID-19 severity

170 Examination of the principal components plot labelling samples by clinical severity at the
171 time of sampling (defined by WHO severity scores, graded as mild, moderate, severe or
172 critical) demonstrated a gradient of COVID-19 severity, best captured by principal
173 components 1 and 3 (**Figure 2 figure supplement 1a**). To determine the proteomic effects

174 of COVID-19 severity, we tested for associations between proteins and WHO severity score
175 at the time of blood sampling, using linear mixed models with severity encoded as an ordinal
176 predictor (**Methods**). This analysis revealed 203 proteins associated with severity (**Figure**
177 **3b, Supplementary File 1d**). The majority of these were upregulated in more severe
178 disease, with only 42 down-regulated. A sensitivity analysis adjusting for time since last
179 haemodialysis, made no significant impact on our results (**Figure 3 figure supplement 4c-**
180 **d, Supplementary File 1d**). Consistent with previous reports, we found that severe COVID-
181 19 was characterised by elevated IL6. In addition, we observed a signature of upregulated
182 monocyte chemokines (e.g. CCL2, CCL7, CXCL10), neutrophil activation and degranulation
183 (e.g. PRTN3, MPO) and epithelial injury (e.g. KRT19, AREG, PSIP1, GRN). (**Figure 3b,c,**
184 **Figure 5**). SERPINA5 and leptin showed the greatest downregulation as COVID-19 severity
185 increased (**Figure 3b,c**).

186

187 We next asked how does the COVID-19 severity protein signature relate to the proteins that
188 are differentially abundant between cases and controls? The majority (140/203; 69%) of
189 severity-associated proteins were also identified as differentially abundant in the COVID-19
190 positive versus negative analysis (**Figure 6a**). Log fold changes for proteins in COVID-19
191 versus non-infected patients were correlated with effect sizes in the severity analysis, such
192 that the proteins most upregulated in cases versus controls also tended to show the greatest
193 upregulation in severe disease (**Figure 6b**). However, there were some notable exceptions
194 (eg CCL20, IL17C, OSM) that were strongly associated with severity but not differentially
195 expressed in infected versus non-infected patients (**Figure 6c**).

196

197 Supervised learning to predict COVID-19 severity

198 Principal components analysis revealed that some samples from patients who had mild or
199 moderate disease at the time of sampling clustered with samples from patients with severe
200 disease (**Figure 2 figure supplement 1a**). Examination of the same PCA plot this time
201 labelling samples according to the patient's overall clinical course (measured by peak WHO
202 severity score over the duration of the illness) (**Figure 2 figure supplement 1b**), revealed
203 that these samples came from individuals who subsequently developed severe or critical
204 disease. This suggested that molecular changes may predate clinical deterioration. To
205 evaluate this further, we used supervised learning approaches to test if the proteomic
206 signature of the first blood sample for each patient in our dataset could identify whether the
207 patient either had clinically severe COVID-19 at the time of sampling or would develop
208 severe disease in the future. Whereas differential expression analyses consider each protein
209 marker separately, machine learning techniques allow examination of all proteins
210 concurrently, thus capturing non-linear relationships in the dataset. Using Random Forests,

211 we trained a classifier on the first sample for each COVID-19 patient to predict the overall
212 clinical course, defined by peak WHO severity. For the purposes of this analysis, we
213 binarised clinical course into either WHO mild/moderate or severe/critical.

214

215 The Random Forests method achieved 71% accuracy in predicting peak severity. By
216 contrast, using only clinically available predictors (demographics, comorbidities and clinical
217 laboratory results), the Random Forests method achieved 66% accuracy in predicting peak
218 severity. Combining clinical parameters plus proteins did not improve accuracy (71%)
219 compared to using proteomic predictors alone, suggesting that the information contained in
220 the clinical predictors is captured at the proteomic level. While we do not believe that
221 proteomic profiling is likely to enter clinical practice for risk stratification during this
222 pandemic, the features selected by the classifier can highlight proteins of biological
223 importance. We therefore interrogated the model to identify key proteins by calculating
224 feature importance metrics (**Methods, Supplementary File 1e**). The most important
225 proteins for indicating the presence of current or future severe disease were IL18BP, CTSD
226 (Cathepsin D), GDF15, KRT19, TNFSF11 and IL1RL1 (ST2) (**Figure 7a**). It is notable that
227 through this distinct analytical approach, KRT19 again emerged as a key biomarker of
228 severe disease.

229

230 Proteins associated with risk of death

231 9/55 patients in subcohort A died. We therefore sought to identify proteins associated with
232 risk of death. To leverage the dynamic nature of repeated protein measurements for
233 prediction of death, we utilised joint models, which combine linear mixed models and Cox
234 proportional hazards models [10,11] (**Methods**). This analysis identified 44 proteins for
235 which increased concentration was associated with increased risk of death (**Figure 7b,**
236 **Supplementary File 1f**), including CST3, IL22RA1, AZU1, CCL28 and SPON1, and 25
237 proteins for which increased concentration was associated with reduced risk of death,
238 including CD84, TNFSF12, TANK, PRKCQ and ADM.

239

240 Associations with clinical laboratory tests

241 A number of routine clinical laboratory tests have well characterised associations with
242 COVID-19 (e.g. elevated inflammatory markers, d-dimer and reduced lymphocyte count)
243 [12]. We therefore compared our proteomic data from COVID-19 patients at each timepoint
244 to contemporaneous clinical laboratory measurements using linear mixed models
245 (**Methods**). We found associations between plasma proteins and all clinical laboratory
246 measurements except troponin (**Figure 8, Supplementary File 1g**). Many of these proteins
247 were also markers of severity (e.g. IL6, KRT19, IFN-gamma and CXCL10 were strongly

248 associated with raised CRP and ferritin and reduced lymphocyte counts). Of note CCL7, a
249 monocyte chemokine that was also identified as an important marker of severity by the
250 Random Forests classifier, was associated with lower monocyte count and raised
251 inflammatory markers. Elevated neutrophil count was associated with Oncostatin-M, which
252 regulates IL6, GCSF and GMCSF production, and with the proteases MMP9 and defensin.

253

254 Longitudinal analysis reveals proteins with distinct temporal profiles according to severity

255 The immune response to infection is dynamic, and therefore snapshot measurements
256 provide only partial insights. Leveraging the dense serial sampling in our dataset (**Figure 1**),
257 we modelled the temporal trajectory of each protein and asked whether or not any protein
258 trajectories differed in patients with a severe/critical versus mild/moderate overall clinical
259 course. This was achieved using linear mixed models that included a term for time from first
260 symptoms and a time x severity interaction term (**Methods**).

261

262 178 proteins displayed a significant association with time from first symptoms (5% FDR),
263 demonstrating the temporal variability in plasma proteins across the disease course
264 (**Supplementary File 1h**). Moreover, we identified 32 proteins for which there was
265 significant interaction between time and severity, i.e. proteins displaying differential temporal
266 trajectories between mild/moderate and severe/critical infections (**Supplementary File 1h**,
267 **Figure 9**). Among the proteins with the strongest temporal differences according to clinical
268 course were the integrins ITGA11 and ITGB6, the adhesion molecule ICAM1, TNFRSF10B
269 (a receptor for TRAIL) and PLAUR, the receptor for urokinase plasminogen activator. Most
270 of these proteins exhibited rising profiles in the more severe patients but flat profiles in milder
271 cases. ACE2, the receptor for SARS-CoV-2, also displayed this pattern (**Figure 9**). In
272 contrast, abundance of ITGA11, which was also identified as reduced in the analysis of
273 infected versus non-infected patients, fell over time in the severe group.

274

275 Testing for proteins associated with ethnicity

276 In the UK, individuals from ethnic minorities are at higher risk of severe disease and death
277 from COVID-19 [4]. We therefore examined whether any of the proteins we measured
278 exhibited differences across ethnicities, analysing COVID-19 positive cases and controls
279 separately (**Methods**). In COVID-19 negative ESKD patients, no proteins were significantly
280 associated with ethnicity in a multivariable model adjusting for age and sex. In COVID-19
281 positive ESKD patients, there is the potential for protein associations with ethnicity to be
282 confounded by disease severity. To account for this, we included severity as well as age and
283 sex as covariates. A single protein, LY75, was associated with ethnicity in this multivariable
284 model (nominal P 0.0001, Benjamini-Hochberg adjusted P 0.04, with higher levels in white

285 patients). Using the same within cases analysis strategy in subcohort B, we found no
286 proteins were significantly associated with ethnicity after multiple testing correction, although
287 the nominal P value for LY75 was 0.025. While these analyses failed to identify substantial
288 ethnicity-related variation in the proteins we measured, an important caveat is that there
289 were relatively modest numbers of individuals from each ethnic group, and so statistical
290 power was limited. Larger multi-ethnic studies are needed to adequately address this
291 question.

292

293 Comparisons to other proteomic studies in COVID-19

294 Other studies have used a variety of proteomic platforms to investigate COVID-19. We
295 compared our findings to those of 3 published studies [13–15] and a preprint by Filbin *et al*
296 [16]. Of the 221 proteins that were differentially abundant in our analysis of COVID-19
297 positive versus negative ESKD patients, 116 associations had been previously reported
298 (**Supplementary File 1i**). Of the 203 proteins associated with severity, 165 had previously
299 been reported (**Supplementary File 1j**).

300

301 We focussed in more detail on the study by Filbin *et al* [16] because of the large sample size
302 and the breadth of proteomic assay used. This study comprised 384 patients with acute
303 respiratory distress (306 COVID-19 positive and 79 COVID-19 negative), and measured
304 1,472 proteins using the Olink Explore platform. 417 of these were also measured in our
305 study. Of the 221 proteins differentially abundant in our case/control analysis, 210 were
306 measured in their study. Of these 100 (47.6%) were significant in their analysis of COVID-19
307 positive versus negative respiratory distress. In addition, we observed strong correlation
308 ($r=0.69$) between the estimated log fold changes in our and their studies (**Figure 4 figure**
309 **supplement 1**). Of the 203 proteins associated with severity in our study, 192 were
310 measured in their study. 157 of these were significantly associated with severity, giving a
311 concordance of 81.8%. Thus, despite the differences in study design and clinical
312 populations, we observed notable similarities in our results and those reported by Filbin *et al*
313 [16].

314

315 **Discussion**

316

317 In this study we performed plasma proteomic profiling of haemodialysis patients with COVID-
318 19. A strength of our study was that we were able to perform serial blood sampling in both
319 the outpatient and inpatient setting, including longitudinal samples from the same individual
320 before and after hospitalisation. This was possible because haemodialysis patients are
321 unable to fully isolate as they must continue to attend for regular dialysis sessions.

322 Moreover, haemodialysis patients represent an important group since ESKD is one of the
323 strongest risk factors for death from COVID-19 [4,6–8]. Data from the UK Renal Registry
324 shows that 7- and 14-day mortality for COVID-19 infected in-centre haemodialysis patients
325 was 11% and 19%, respectively [17]. Data from the Scottish Renal Registry estimates 30-
326 day mortality following a positive COVID-19 test as 22%, and as of 31 May 2020, 28.2% of
327 renal replacement therapy patients who had a positive COVID-19 test had died [18]. In our
328 local population of 1,352 in-centre haemodialysis patients, 315 patients had tested positive
329 for COVID-19 by the end of our study period (31 May 2020), of whom 53% required
330 hospitalisation and 85 (27%) died. The OpenSAFELY study [4] examined ~17 million UK
331 primary care records and linked these to the UK COVID-19 mortality register. Patients with
332 estimated glomerular filtration rate (eGFR) $<30\text{ml/min/1.73m}^2$ had a hazard ratio (HR) for
333 death of 3.56 after adjustment for age and sex.

334

335 In part, the high mortality from COVID-19 in ESKD patients likely reflects the fact that these
336 patients are enriched for cardiometabolic traits that predispose to severe COVID-19.
337 However, in multivariable analyses adjusting for these factors, impaired renal function
338 remains an independent risk factor for severe COVID-19 [4]. Moreover, there is an inverse
339 relationship between renal function and risk of death from COVID-19 across the spectrum of
340 chronic kidney disease. These observations support the notion that the state of ESKD *per se*
341 is an important determinant of outcome in COVID-19. ESKD is well recognised as an
342 immunosuppressed state [19–21], with defects in both innate and adaptive immunity [22–
343 25]. Accordingly, ESKD confers increased vulnerability to viral infections including influenza
344 and respiratory syncytial virus [26–29]. In addition, ESKD results in a chronic low-grade
345 inflammatory state [30]. This tendency to a pro-inflammatory state, combined with reduced
346 ability to respond to viruses, may contribute to the abnormal host response to SARS-CoV-2
347 infection, producing the immunopathology that leads to severe COVID-19.

348

349 Our comparison of COVID-19 positive and negative haemodialysis patient plasma samples
350 revealed 221 proteins that were differentially abundant in COVID-19. The majority of these
351 were upregulated, with strong representation of viral response proteins (e.g. DDX58, IFNG),
352 cytokines/chemokines (e.g. IL6, CCL7, CXCL10 and CXCL11) and epithelial proteins (e.g.
353 KRT19, PSIP1) (**Figure 3a**). The COVID-19 negative controls in this analysis were carefully
354 matched to cases in terms of age, sex and ethnicity. However, complete matching of clinical
355 characteristics was not feasible; there were differences in the prevalence of diabetes and the
356 underlying causes of ESKD between COVID-19 positive cases and controls (**Table 1**).
357 Sensitivity analyses adjusting for these covariates gave highly consistent results, indicating

358 that our findings are robust. In addition, we validated our findings when we analysed serum
359 samples from a separate subcohort of COVID-19 positive ESKD patients.

360

361 ESKD is itself likely to significantly impact the plasma proteome. Previous cross-sectional
362 studies have shown that the levels of many circulating proteins have an inverse relationship
363 with eGFR [31,32]. A longitudinal study using an Olink proteomics panel (although not one
364 used in our study) found that for 74% of the 84 proteins measured, protein levels rose as
365 eGFR fell [33]. For many proteins, it is unclear whether this inverse relationship with renal
366 function reflects cause or effect. Some proteins may be increased in chronic kidney disease
367 due to reduced renal clearance, some may be elevated secondary to tissue injury or chronic
368 inflammation, and others may be drivers of renal injury. Regardless, this observation of
369 widespread changes in the blood proteome of kidney disease patients emphasises the
370 importance of using COVID-19 ESKD patients rather than healthy individuals as our control
371 group.

372

373 Analysis within COVID-19 cases revealed 203 proteins associated with disease severity, the
374 strongest of which was IL6 (**Figure 3b**). Association of IL6 with severe disease is well-
375 established and has already received considerable attention [34,35]. Despite promising initial
376 case reports of IL6R receptor blockade in COVID-19, convincing efficacy was not
377 demonstrated in early randomised trials [36]. More recently, the REMAP-CAP trial has
378 shown the benefit of anti-IL6R therapy when given to critically ill patients on admission to
379 intensive care units [2], indicating that IL6 does contribute to critical illness from COVID-19.
380 Our finding that IL6 was most strongly upregulated in severe disease demonstrates the
381 value of plasma proteomic profiling in identifying putative drug targets.

382

383 Members of the CCL and CXCL chemokine families (e.g. CCL2, CCL7, CCL20 and
384 CXCL10) were strongly associated with severity. Likewise, higher levels of CCL2, CCL7,
385 CCL20 and CXCL10 were associated with lower blood lymphocyte count and higher
386 inflammatory markers (CRP and ferritin) (**Supplementary File 1g**), which are clinical
387 markers of severe disease and poorer outcome in COVID-19 [37]. Of note, CCL20 is a
388 chemoattractant for lymphocytes [38], and its negative association with lymphocyte count
389 may reflect a direct effect on migration of lymphocytes from the blood into the tissues rather
390 than simply marking severe disease. CCL2 (also known as MCP-1) and CCL7 (MCP-3), are
391 both chemokines for monocytes, and CXCL10 has pleiotropic immunological effects
392 including chemotaxis. These chemokines were also negatively correlated with blood
393 monocyte count, suggesting recruitment of these innate immune cells into damaged tissues.

394

395 The neutrophil proteases PRTN3 (proteinase-3) and MPO (myeloperoxidase) (**Figure 5**) and
396 the neutrophil-derived protein AZU1 were associated with severe disease (**Supplementary**
397 **File 1d**), indicating that neutrophil activation and degranulation are features of severe
398 COVID-19. Degranulation of neutrophils releasing PRTN3 and MPO could potentially
399 contribute to oxidative damage in the lungs and thus more severe disease.

400

401 A striking finding of our study was the association of disease severity with upregulation of
402 epithelial proteins (e.g. KRT19) and epithelial tissue repair pathways (e.g. PSIP1, AREG,
403 GRN (progranulin)), most likely reflecting lung and vascular damage. KRT19 was notably
404 prominent in our analyses, as well as the study by Filbin *et al.* [16](**Supplementary File 1j**).
405 KRT19 is an intermediate filament protein, important for the structural integrity of epithelial
406 cells [39]. These data suggest that severe COVID-19 is characterised by destruction of the
407 lung epithelium and vascular endothelium. Vascular injury might thus explain the high level
408 of vascular thrombosis seen in patients in severe disease. In summary, our data reveal that
409 severe COVID-19 is characterised proteomically by a signature of innate immune activation
410 and epithelial injury.

411

412 69% of proteins associated with severity were also differentially abundant in the case versus
413 control analysis (**Figure 6a**), and for the large majority of proteins the within-cases severity
414 analysis effect size was proportional to the fold change between cases and controls (**Figure**
415 **6b**). This suggests that, in general, the distinction in the plasma proteome between severe
416 and mild COVID-19 is a quantitative difference in the COVID-19 signature, rather than there
417 being an orthogonal signature involving a different set of proteins. Consistent with this
418 concept, examination of PCA plots coloured by severity revealed that while there was a
419 gradient of COVID-19 severity, the samples from severe or critical patients did not form a
420 discrete cluster distinct from those from patients with milder disease (**Figure 2 figure**
421 **supplement 1**). However, there were a few exceptions where proteins that were associated
422 with severity were not upregulated in the case-control analysis. These included OSM, IL17C,
423 and CCL20 (**Figure 6c**). These proteins therefore reflect biological processes specifically of
424 severe disease and may represent therapeutic targets.

425

426 Survival analysis identified 44 proteins associated with increased risk of death (**Figure 7b**).
427 As expected, many of these were also associated with disease severity, high CRP and lower
428 lymphocyte count (**Figure 7 figure supplement 1**). In contrast, 25 proteins were associated
429 with reduced risk of death (**Figure 7b**). One such protein is the multi-functional cytokine
430 TNFSF12 (TWEAK). Although TWEAK can exert pro-inflammatory effects, it also can inhibit
431 the innate immune response [40] and promote tissue repair and endothelial cell proliferation

432 and survival [41], which may be beneficial responses in COVID-19. This illustrates that
433 although proteins associated with inflammation are often thought to be destructive, the
434 inflammatory response also induces a programme for limiting injury and initiating tissue
435 repair. Insufficient activation of such homeostatic mechanisms may contribute to why some
436 individuals get severe COVID-19.

437

438 The host immune response to COVID-19 is a dynamic process, and clinical deterioration
439 typically occurs 7-10 days after first symptoms. Temporal information may therefore be
440 important in determining optimum timing of therapeutic intervention (e.g. blockade of a
441 particular cytokine). By taking serial samples and examining their patterns within individuals
442 over time, we were able to model protein trajectories and found that many proteins display
443 temporal variability during COVID-19. Longitudinal measurements also allow molecular
444 comparison of severe versus mild disease trajectories. By modelling the interaction term
445 between time from first symptoms and overall disease course, we found 32 proteins that
446 displayed distinct temporal profiles in severe vs mild disease. These results point to
447 enhanced leucocyte-endothelial cell interactions indicated by upregulation of cell adhesion
448 molecules (e.g. ITGB6, ICAM1) in severe disease. This endothelial activation may contribute
449 to COVID-19-associated thrombosis discussed above. Management of thrombosis in
450 COVID-19 currently consists of anticoagulation. Our results suggest that disrupting
451 leucocyte-endothelial interactions may be a complementary therapeutic strategy.

452

453 Several proteins associated with either risk of death or clinical severity lie in pathways
454 targeted by existing drugs. PARP1 was identified as an important marker of current or future
455 severe COVID-19, and also was associated with risk of death. PARP1 is associated with
456 inflammatory and vascular disease [42]. PARP1 inhibitors are in use for cancer [43], and our
457 data suggest that re-purposing of PARP1 inhibition in COVID-19 should be explored further.
458 IL33 was associated with both risk of death and clinical severity, and its receptor IL1RL1
459 (ST2) was associated with clinical severity and identified as an important predictor of severe
460 clinical course. Monoclonal antibodies against IL33 and its receptor are in late-stage
461 development for asthma [44], and could also be explored in COVID-19. As discussed above,
462 MPO was associated with clinical severity. MPO inhibitors [45] might have a role in reducing
463 neutrophil-mediated tissue injury in COVID-19. Finally, inhibitors of monocyte chemokines
464 (e.g. CCL2) and their receptors have been developed [46,47], although drugging these
465 pathways is made more challenging by molecular cross-talk. An important caveat is that we
466 cannot determine whether the associations we observed are drivers of pathology in COVID-
467 19 or simply reflect the downstream consequences of inflammation and tissue injury. Future

468 studies using Mendelian randomisation analysis will provide a useful tool for assessing
469 causality and prioritizing drug targets.

470

471 Other groups have studied the plasma or serum proteome in COVID-19 [13–16,48], using
472 either mass spectrometry or immunoassays including the Olink platform. Mass spectrometry
473 is less sensitive than immunoassays and so it likely to be unable to detect many of the
474 cytokines measured here. Conversely, it can provide complementary information by
475 measuring many proteins that our immunoassays did not target. A limitation of our study was
476 that we used Olink panels that measured specific proteins selected on their relevance to
477 inflammation, immunity, cardiovascular and metabolic disease. This bias precluded formal
478 pathway enrichment analysis. In general, our results had greater similarities to studies that
479 used immunoassays over mass spectrometry (**Supplementary File 1i-j**). 47.6% of proteins
480 differentially expressed in COVID-19 positive versus negative ESKD patients in our study
481 were differentially expressed in COVID-19 positive versus negative acute respiratory distress
482 syndrome patients in the study of Filbin et al [16], who used a different Olink proteomics
483 platform. Moreover, we observed consistent effect sizes (**Figure 4 figure supplement 1**).
484 These similarities are striking given the difference in clinical populations and control groups;
485 in Filbin *et al's* report the controls included patients with non-COVID-19 respiratory infections
486 whereas our control group did not have active infection. The concordance in proteins
487 associated with COVID-19 severity within cases was even higher (81.8%). The similarities
488 suggests a similar plasma proteomic signature of COVID-19 across different clinical
489 populations, particularly the signature associated with severity.

490

491 In summary, this study reveals proteins associated with COVID-19 infection and severity,
492 and demonstrates altered dynamic profiles between patients with severe disease and those
493 with a more indolent course. Our results emphasise the importance of studying and targeting
494 mechanisms that reduce the lung epithelial and endothelial damage to both alleviate the
495 severity of the infection and to reduce the chance of long-lasting complications. These data
496 provide a valuable resource for therapeutic target prioritisation.

497

498 **Materials and Methods**

499

500 Subjects and samples

501 *Ethical approval:* All participants (patients and controls) were recruited from the Imperial
502 College Renal and Transplant Centre and its satellite dialysis units, London, and provided
503 written informed consent prior to participation. Study ethics were reviewed by the UK
504 National Health Service (NHS) Health Research Authority (HRA) and Health and Care

505 Research Wales (HCRW) Research Ethics Committee (reference 20/WA/0123: The impact
506 of COVID-19 on patients with renal disease and immunosuppressed patients). Ethical
507 approval was given.

508

509 *Subcohort A:* We recruited 55 COVID-19 positive haemodialysis patients, either as
510 outpatients or as inpatients (**Table 1**). All patients were receiving in-centre outpatient
511 haemodialysis prior to COVID-19 diagnosis. COVID-19 was confirmed in all cases with
512 positive nasal PCR for the SARS-CoV-2 virus. Patients were recruited during the first UK
513 national lockdown, with recruitment from 8th April – 30th May 2020. Blood was collected in
514 EDTA tubes and centrifuged to obtain plasma, and stored at –80°C. Sample processing was
515 performed within 4 hours of venepuncture. The initial sample was taken as an outpatient for
516 30 patients and as an inpatient for 25. Where feasible, serial blood samples were taken. In
517 total, 259 samples were taken (3 subsequently failed QC – see below). The median number
518 of serial samples was 5 (range 1-10) (**Figure 1 figure supplement 1d**). 8 patients who were
519 recruited as outpatients were subsequently admitted to hospital with COVID-19 over the
520 course of the study. 27 of 55 (49.1%) patients had severe or critical disease (defined by
521 peak WHO severity). 9 (16.4%) patients died.

522

523 In addition, we recruited 51 COVID-19 negative haemodialysis controls. COVID-19 negative
524 haemodialysis controls were selected to mirror the cases in terms of demographic features
525 (age, sex, ethnicity) (**Figure 1 figure supplement 1a-c**). These control patients had no
526 clinical features of any other infection.

527

528 *Subcohort B:* We also recruited a separate set of 46 COVID-19 positive haemodialysis
529 patients (**Table 2**). These patients were recruited from the same centre, but slightly earlier
530 than subcohort A (recruitment commenced on 30th March 2020). For these patients, blood
531 was collected in serum tubes and centrifuged to obtain serum. At this time, we had very
532 limited access to laboratory facilities and so plasma was not collected from these patients. 5
533 were outpatients and 41 were inpatients, reflecting the fact that UK policy was weighted
534 towards inpatient testing at the time these patients were recruited. 33 of 46 patients (71.7%)
535 had severe or critical disease (by peak WHO severity), and 9 (19.6%) patients died. For 40
536 patients, only one sample from a single timepoint was collected, and for 6 patients, 2
537 samples were collected. To provide controls for subcohort B, we used serum samples from
538 11 non-infected haemodialysis patients (collected at the same time as plasma from a subset
539 of the ESKD control group described above).

540

541 Clinical severity scores

542 Severity scoring was performed based on WHO classifications (WHO clinical management
543 of COVID-19: Interim guidance 27 May 2020) adapted for clinical data available from
544 electronic medical records. ‘Mild’ was defined as COVID-19 symptoms but no evidence of
545 pneumonia and no hypoxia. ‘Moderate’ was defined as symptoms of pneumonia or hypoxia
546 with oxygen saturation (SaO₂) greater than 92% on air, or an oxygen requirement no greater
547 than 4L/min. ‘Severe’ was defined as SaO₂ less than 92% on air, or respiratory rate more
548 than 30 per minute, or oxygen requirement more than 4L/min. ‘Critical’ was defined as organ
549 dysfunction or shock or need for high dependency or intensive care support (i.e. the need for
550 non-invasive ventilation or intubation). Severity scores were charted throughout a patient’s
551 illness. We defined the overall severity/clinical course for each patient as the peak severity
552 score that occurred during the patient’s illness.

553

554 Proteomic assays

555 Plasma and serum proteomic measurements were performed using Olink proximity
556 extension immunoassays (<https://www.olink.com/products/>). Five 92-protein multiplex Olink
557 panels were run (‘inflammation’, ‘immune response’, ‘cardiometabolic’, ‘cardiovascular 2’ and
558 ‘cardiovascular 3’), resulting in 460 measurements per sample. Since a small number of
559 proteins were measured on more than one panel, we measured a total of 436 unique
560 proteins. The Olink assays were run using 88 samples/plate. All plates were run in a single
561 batch. Plate layouts was carefully designed to avoid confounding of potential plate effects
562 with biological or clinical variables of interest. To achieve this, we used an experimental
563 design that combined ensuring case/control balance across plates with random selection of
564 samples from each category and random ordering of allocation to wells. This is outlined in
565 more detail as follows. We ensured that each plate contained a mixture of control and case
566 samples. Specifically, a fixed proportion of each plate was designated for control samples.
567 The allocation of specific control samples to each plate was performed using randomisation.
568 For the case samples, we again used randomisation for plate assignment, with the constraint
569 that once one sample from a given patient was allocated to a plate, all other longitudinal
570 samples from that patient were assigned to same plate. Finally, once all the samples had
571 been allocated to plates, the layout of samples within each plate was determined through a
572 further randomisation step for well allocation.

573

574 Protein annotation

575 We used the Human Protein Atlas version 20.0 [49] for protein annotation (**Figure 1 figure**
576 **supplement 2**). We performed enrichment analysis of the 436 proteins that we measured
577 using string-db [50].

578

579 Normalisation and quality assessment and control

580 The data was normalised using standard Olink workflows to produce relative protein
581 abundance on a log₂ scale ('NPX'). Quality assessment was performed by a) examination of
582 Olink internal controls, and b) inspection of boxplots, relative log expression (RLE) plots [51]
583 and PCA. Following these steps, 3 poor quality samples were removed. In addition, 5
584 samples failed quality control on a single proteomic panel only, with the remaining panels
585 passing QC. For these samples, proteins on the panel that failed QC were set to missing,
586 and the data for the remaining proteins was retained.

587

588 Principal components analysis revealed no substantial impact of plate effects (**Figure 2**
589 **figure supplement 2**). 13 proteins were assayed more than once due to their inclusion in
590 multiple Olink panels. For plasma, the median correlation between the assays was 0.986
591 with an IQR of 0.974-0.993 and a range of 0.925 to 0.998. For serum, the median correlation
592 between the assays was 0.991 with an IQR of 0.952-0.995 and a range of 0.737-0.999. We
593 removed duplicate assays at random prior to subsequent analyses.

594

595 For 11 ESKD controls, we had contemporaneous plasma and serum samples. To assess the
596 comparability of these two matrices, we calculated the Pearson's correlation coefficient
597 between the assays for each protein (**Supplementary File 1k**). 344/436 (78.9%) of proteins
598 had a Pearson's $r > 0.5$. We also report the variance of each protein in plasma and serum
599 since low correlation may reflect low variance. The proteins with the lowest estimated
600 Pearson correlation coefficient were AZU1, STK4 and TANK. We highlight that this
601 comparison had small sample size (only 11 samples) and that the samples were from control
602 patients without infection. Caution should be made in extrapolating these findings to the
603 context of active infection where protein dynamic ranges may be different.

604

605 Missing values

606 Following QC, 0.22% data points were missing for the plasma dataset and 0.35% for the
607 serum dataset. For analyses that required no missing values (PCA and supervised learning),
608 we imputed missing values as follows. The dataset was first scaled and centred, and missing
609 values imputed using caret's k-nearest neighbours (kNN) method [52]. The 5 closest
610 samples (by Euclidean distance) were used to estimate each missing value.

611

612 Principal Components Analysis

613 Singular value decomposition was used to perform PCA on the proteomic data from
614 subcohort A (plasma samples). We then used the loadings from subcohort A together with

615 the proteomic data from subcohort B to calculate principal components scores. This enabled
616 projection of subcohort B data into the PCA space of subcohort A.

617

618 Differential protein abundance analysis: COVID-19 positive versus negative

619 Differential protein abundance analyses between COVID-19 positive and negative samples
620 were performed using linear mixed models, to account for the use of serial samples from the
621 same individuals (R lme4 package [53]). This analysis compared 256 samples from 55
622 COVID-19 patients with 51 non-infected patients (1 sample per non-infected patients). Age,
623 sex and ethnicity were included as covariates. We used a random intercept term to estimate
624 the variability between individuals in the study and account for repeated measures. The
625 regression model in R notation was:

626
$$\text{NPX} \sim \text{covid_status} + \text{sex} + \text{age} + \text{ethnicity} + (1 \mid \text{individual})$$

627 where NPX represents the protein abundance and covid_status was a categorical variable
628 (infected/non-infected). Sex and ethnicity were also categorical variables. Age was a
629 quantitative variable. We calculated P values using a type 3 F test in conjunction with
630 Satterthwaite's method for estimating the degrees of freedom for fixed effects [54]. The
631 regression model was fitted for each of the 436 proteins individually. Multiple testing
632 correction was performed using the Benjamini-Hochberg method and a 5% FDR used for the
633 significance threshold.

634

635 The same approach was used for subcohort B. This analysis comprised 52 serum samples
636 from 46 COVID-19 positive patients versus 11 samples from non-infected patient samples (1
637 sample per non-infected patient).

638

639 As sensitivity analyses, we repeated the differential abundance analyses between case and
640 controls for the subcohort A adjusting for additional covariates and comparing this to the
641 basic model (i.e. using age, sex, and ethnicity alone). This was performed for each of the
642 following parameters: diabetes status, cause of ESKD, and time to last haemodialysis.

643

644 Testing for associations between proteins and clinical severity

645 For testing the association of plasma proteins with the 4-level WHO severity rating (mild,
646 moderate, severe and critical) within COVID-19 positive cases from subcohort A (n=256
647 samples from 55 patients), we used a similar linear mixed modelling approach to the COVID-
648 19 positive versus negative differential abundance analysis; for this analysis, the
649 covid_status term was replaced by a severity variable encoded using orthogonal polynomial
650 contrasts to account for ordinal nature of severity levels. As before, age, sex and ethnicity

651 were included as covariates. As a sensitivity analysis, we repeated the analysis with time to
652 last haemodialysis (days) as an additional covariate.

653

654 Testing for associations between proteins and clinical laboratory tests

655 The linear mixed modelling strategy was also employed for testing association of temporal
656 clinical laboratory variables and protein levels, with the value of the clinical variable (as a
657 quantitative trait) used in place of covid_status. Only COVID-19 positive patients were
658 included in this analysis. Contemporaneous lab measurements were not available for all
659 samples. This varied according to the clinical lab parameter. Some (eg troponin, d-dimer)
660 were measured less frequently than full blood count and CRP. Details of the proportion of
661 missing values for each lab parameter are included in (**Supplementary File 1g**). We also
662 calculated correlations between clinical laboratory variables and protein levels using the R
663 package rmcrr, which determines the overall within-individual relationship among paired
664 measures that have been taken on two or more occasion [55].

665

666 Testing for associations between proteins and ethnicity

667 We performed testing of protein levels and ethnicity separately in COVID-19 negative ESKD
668 patients and COVID-19 positive ESKD patients. These analyses were limited to individuals
669 who were White, South Asian (Indian, Pakistani or Bangladeshi ancestry) or Black as there
670 were too few individuals from other ethnic groups for meaningful interpretation. For COVID-
671 19 negative patients (1 sample per patient), we performed linear regression for each protein
672 with ethnicity as the predictor variable, and age and sex as covariates. For COVID-19
673 positive patients we used a linear mixed model to account for serial samples from the same
674 individual, again with age, and sex as covariates.

675

676 Multiple testing correction

677 We used the Benjamini-Hochberg method to control the FDR at 5% for all statistical
678 analyses.

679

680 Alternative estimation of the FDR using the plug-in method

681 To provide additional support that the Benjamini-Hochberg procedure was providing
682 adequate control of the FDR, we also used the plug-in method of Tibshirani [9] as an
683 alternative method to estimate the FDR, as described below.

684 1. We defined R as the number of associations declared significant in the real data.

685 2. We defined C as the test statistic used as the significance threshold used in the real data
686 (i.e. that corresponding to an adjusted p-value of 0.05).

687 3. The expected number of proteins that we would find significant under the null hypothesis
688 that no proteins are differentially abundant between COVID-19 positive versus negative
689 patients (i.e. false positives) was estimated using a permutation strategy. We randomly
690 permuted each individuals' COVID-19 status label 100,000 times and, in each case,
691 repeated the differential abundance analysis on the permuted data. The estimated the
692 number of false positives (\hat{V}) was then estimated by the number of associations with test
693 statistic $> C$ in 100,000 permutations of the data, divided by the number of permutations.

694 4. The estimated FDR was then calculated as \hat{V}/R .

695

696 We implemented a similar approach for the testing the association of proteins with severity
697 scores within cases.

698

699 Using this method, the estimated FDR for the case versus control analysis was 0.062 and for
700 the severity analysis 0.057, indicating that we had appropriately controlled the FDR.

701

702 Empirical p-value calculation

703 As a complementary analysis, based on the approach of Filbin *et al.* [16], we estimated the
704 empirical P-value for the likelihood of observing as many significant proteins as we identified
705 in the real data if the null hypothesis of no differentially abundant proteins in cases versus
706 controls were true. We again used 100,000 permutations of the case control labels to
707 estimate the null distribution. We performed Benjamini-Hochberg adjustment on the nominal
708 p-values of each permutation, and counted the number of proteins that were significant
709 (adjusted p-value < 0.05) in each permutation.

710 The distribution of the number of proteins declared significant is shown in **Figure 3 figure**
711 **supplement 2a**; on no occasion in 100,000 permutations did we observe more proteins
712 declared significant than in the real data. We can thus state that the empirical P-value (the
713 fraction of permutation runs where we observed \geq the number of associations in the real
714 data) is less than $1/100,000 = 1 \times 10^{-5}$.

715

716 We also applied this method to the association testing of proteins with severity scores within
717 cases (**Figure 3 figure supplement 2b**). Again, on no occasion in 100,000 permutations did
718 we observe more proteins declared significant than in the real data (empirical p-value $< 1 \times 10^{-5}$).
719

720

721 Supervised learning

722 Random forest models were fit using R's randomForest and caret packages [52,56]. Data
723 was centred, scaled and imputed as in *Data Preparation* with the caveat that, during cross-
724 validation, the pre-processing procedure was first applied on the resampled (training) data
725 before the same method was applied without re-calculation to the holdout (test) set. To
726 estimate model accuracy, we used 4-fold cross-validation. The cross-validation procedure
727 was repeated 100 times. The model's parameters were kept constant at 500 trees and an
728 mtry value (number of proteins randomly sampled as candidates at each node) calculated as
729 the square root of the number of features. After parameter estimation, we fit a final model
730 trained using the entirety of the dataset. This model was used for subsequent feature
731 extraction. Random forest feature extraction was carried out using the R
732 randomForestExplainer package. We made use of the following importance measures:
733 accuracy decrease (the average decrease in prediction accuracy upon swapping out a
734 feature), number of trees (the number of trees with a node corresponding to a feature) and
735 mean minimal depth (the average depth at which a node corresponding to a feature occurs).
736 Three models were generated with different input features: i) proteomic data alone; ii) clinical
737 parameters alone; iii) proteomic data and clinical parameters. Clinical parameters included
738 sex, age, ethnicity, cause of ESKD, comorbidities, smoking status, radiological evidence of
739 pulmonary infiltrates, and clinical laboratory tests.

740

741 Survival analysis using joint modelling

742 Following scaling and centering, we fit linear mixed models for each protein to capture the
743 temporal trajectories of each individual. A polynomial spline of degree 2 was used to model
744 protein concentration with respect to time (from symptom onset, measured in days); the
745 spline was fitted for samples that were taken between 1 and 28 days from first symptoms,
746 inclusive. Proteomic data after that point was censored. We estimated both random
747 intercepts and random slopes for each individual, as per the following R formula notation:

748

$$\text{NPX} \sim \text{time} + (\text{time} \mid \text{individual})$$

749 These were joined to a Cox regression model using the jointModel package [11] in order to
750 estimate the association of each protein with risk for death. P values were calculated using a
751 Wald test for the association between the linear mixed model and Cox regression.
752 Benjamini-Hochberg adjustment was applied, with an adjusted p-value of 0.05 used as the
753 significance threshold.

754

755 Longitudinal analysis

756 We also used linear mixed models to estimate the temporal profile of each protein. For this
757 longitudinal analysis we explicitly modelled the time from first symptoms. We set up the

758 model to test for each protein a) whether the protein significantly change over time and b)
759 whether the protein changes over time differently in individuals with a mild versus severe
760 disease course. The latter was performed statistically by testing for an interaction effect
761 between time and clinical course. For the purposes of this analysis, we binarised patients
762 into severe or non-severe clinical course according to the peak WHO severity disease of
763 their illness. Patients with a peak WHO score of mild or moderate were considered non-
764 severe and those with a peak score of severe or critical were considered severe.

765

766 We then used R's `bs` function to fit a polynomial spline of degree 2 to model protein
767 concentration with respect time (from symptom onset, measured in days) [57]. The spline
768 was fit for samples that were taken between 1 and 21 days from symptom onset, inclusive.
769 We estimated random slopes with respect to time, in addition to random intercepts, to
770 account for each individual's unique disease course. For each protein, we fitted the following
771 model (R notation):

772
$$\text{NPX} \sim \text{time} * \text{severity} + \text{sex} + \text{age} + \text{ethnicity} + (\text{time} | \text{individual})$$

773 To identify proteins that changed significantly over time, we examined the P-values for the
774 main effect of time. To identify proteins with distinct temporal profiles between severe and
775 non-severe cases, we examined the P values for the time x severity interaction term. For
776 each of these two research questions, P-values were adjusted for the multiple proteins
777 tested using the Benjamini-Hochberg method and 5% FDR used as the significance
778 threshold.

779

780 **Data availability statement**

781 All data generated during this study are included in the manuscript and supporting files.
782 Underlying source data for all analyses (individual-level proteomic and clinical phenotyping
783 data) are available without restriction as **Source Data Files 1-4**. In addition, these data have
784 been deposited in the Dryad Digital Repository (doi:10.5061/dryad.6t1g1jwxj).

785

786 **Code availability:** code is available in the following GitHub repository:

787 https://github.com/jackgisby/longitudinal_olink_proteomics

788

789 **Author contributions:**

790 Conceived and designed the study: MCP, MB, MW, DCT, JEP.

791 Funding acquisition: JB, MCP, MB, MW, DCT, JEP.

792 Patient recruitment and sample collection: CLC, NM-T, ES, SPM, MFP, MW, DCT.

793 Led and coordinated patient recruitment: MW.

794 Sample processing: THM, PMM, NBB, SL, MP, FT, EF, M-A M, ED, LT, MB.

795 Clinical phenotyping: CLC, NM-T, SL, ES, MFP, MCP, JEP.

796 Data analysis: JG, AP.

797 Supervised the analysis: JEP.

798 Statistical support: PK, ACR.

799 Wrote the paper: JG, JEP

800 Results interpretation and editing the paper: MB, MCP, DT, ACR, JB.
801 All authors critically reviewed and approved the manuscript before submission.

802

803 **Acknowledgements**

804 The authors thank the patients who volunteered for this study and the staff at Imperial
805 College Healthcare NHS Trust (the Imperial College Healthcare NHS Trust renal COVID-19
806 group and dialysis staff):

807

808 Appelbe M, Ashby DR, Brown EA, Cairns T, Charif R, Condon M, Corbett RW, Duncan N,
809 Edwards C, Frankel A, Griffith M, Harris S, Hill P, Kousios A, Levy JB, Loucaidou M,
810 Lightstone L, Liu L, Lucisano G, Lynch K, Mclean A, Moabi D, Muthusamy A, Nevin M,
811 Palmer A, Parsons D, Prout V, Salisbury E, Smith C, Tam F, Tanna A, Tansey K, Tomlinson
812 J, Webster P.

813

814 We also acknowledge the efforts of renal specialist doctors in training for assistance with
815 recruiting patients to this study.

816

817 We also thank:

818 - Hari and Rachna Murgai and Milan and Rishi Khosla for generous support with sample
819 transport.

820 - Dr Kerry Rostron for exceptional support with laboratory facilities in challenging
821 circumstances and the Department administrators for their help.

822 - Dr Brian Tom and Dr Jessica Barrett (MRC Biostatistics Unit, University of Cambridge) for
823 statistical advice.

824 - Prof Sir John Savill (Melbourne Academic Centre for Health) for comments on the
825 manuscript.

826

827 **Funding statement**

828 This research was partly funded by Community Jameel and the Imperial President's
829 Excellence Fund and by a UKRI-DHSC COVID-19 Rapid Response Rolling Call
830 (MR/V027638/1) (to JEP). We also acknowledge a contribution from UKRI/NIHR through the
831 UK Coronavirus Immunology Consortium (UK-CIC) and the National Institute for Health
832 Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS
833 Trust and Imperial College London. The views expressed are those of the author(s) and not
834 necessarily those of the NHS, the NIHR or the Department of Health. JEP is supported by
835 UKRI Innovation Fellowship at Health Data Research UK (MR/S004068/2). DCT is
836 supported by a Stage 2 Wellcome-Beit Prize Clinical Research Career Development
837 Fellowship (20661206617/A/17/Z and 206617/A/17/A) and the Sidharth Burman endowment.
838 MCP is a Wellcome Trust Senior Fellow in Clinical Science (212252/Z/18/Z). NM-T and ES
839 are supported by Wellcome Trust and Imperial College London Research Fellowships, and
840 CLC by an Auchi Clinical Research Fellowship. PDWK is supported by the UK Medical
841 Research Council (MC_UU_00002/13).

842

843 The funders had no role in study design, data collection and interpretation, or the decision to
844 submit the work for publication.

845

846 **Competing interests:**

847 None of the authors have any patents (planned, pending or issued) relevant to this work. Dr.
848 McAdoo reports personal fees from Celltrion, Rigel, GSK and Cello, unrelated to the
849 submitted work. Dr Peters has received travel and accommodation expenses and hospitality

850 from Olink to speak at Olink-sponsored academic meetings. None of the other authors have
851 any competing interests.
852
853

854 **Figure Legends**

855

856 **Figure 1 – Study design.**

857 **a)** Schematic representing a summary of the patient cohorts, sampling and the major
858 analyses. Blue and red stick figures represent outpatients and hospitalised patients,
859 respectively. **b)** Timing of serial blood sampling in relation to clinical course of COVID-19
860 (subcohort A). Black asterisks indicate when samples were obtained. Three patients were
861 already in hospital prior to COVID-19 diagnosis (indicated by red bars).

862

863 **Figure 1 figure supplement 1 – Baseline characteristics of subcohort A.**

864 The number of COVID-19 positive and negative patients in subcohort A (plasma), stratified
865 by: **a)** sex, **b)** age, and **c)** ethnicity. **d)** Serial samples obtained for COVID-19 patients.

866

867 **Figure 2 – Principal components analysis.**

868 PC = principal component. Each point represents a sample. Colouring indicates COVID-19
869 status. The directions and relative sizes of the 6 largest PC loadings are plotted as arrows
870 (middle column).

871 **a-b)** Subcohort A. Due to serial sampling, there are multiple samples for most patients. The
872 proportion of variance explained in subcohort A by each PC is shown in parentheses on the
873 axis labels. **c-d)** Subcohort B. Samples are projected into the PCA coordinates from
874 subcohort A.

875

876 **Figure 2 figure supplement 1 – Principal components analysis in relation to clinical
877 severity.**

878 **a)** Colouring indicates WHO severity at time of sampling. **b)** Colouring indicates overall
879 clinical course (indicated by peak WHO severity) for the patient from which that sample was
880 taken.

881

882 **Figure 2 figure supplement 2 – Principal components analysis in relation to assay
883 plate.**

884 Principal components analysis of the subcohort A coloured by plate.

885

886 **Figure 3 – Identification of dysregulated proteins.**

887 **a) Proteins up-regulated (red) or down-regulated (blue) in COVID-19 positive patients
888 versus negative ESKD patients.** n= 256 plasma samples from 55 COVID-19 positive
889 patients, versus n= 51 ESKD controls (1 sample per control patient).

890 **b) Proteins associated with disease severity.** Associations of protein levels against WHO
891 severity score at the time of sampling. Linear gradient indicates the effect size. A positive
892 effect size (red) indicates that an increase in protein level is associated with increasing
893 disease severity and a negative gradient (blue) the opposite. n= 256 plasma samples from
894 55 COVID-19 positive patients. For **a)** and **b)**: P-values from linear mixed models after
895 Benjamini-Hochberg adjustment; significance threshold= 5% FDR; dark-grey = non-
896 significant.

897 **c) Heatmap showing protein levels for selected proteins with strong associations with
898 severity.** Each column represents a sample (n=256 COVID-19 samples and 51 non-infected
899 samples). Each row represents a protein. Proteins are annotated using the symbol of their
900 encoding gene. For the purposes of legibility, not all significantly associated proteins are
901 shown; the heatmap is limited to the 17% most up- or down-regulated proteins (by effect
902 size) of those with a significant association. Proteins are ordered by hierarchical clustering.
903 Samples are ordered by WHO severity at the time of blood sample ('Severity'). 'Overall
904 course' indicates the peak WHO severity over the course of the illness.

905

906 **Figure 3 figure supplement 1. Differential abundance analysis between ESKD patients
907 with and without COVID-19.**

908 Heatmap showing selected proteins with the largest fold changes in differential abundance
909 analysis (subcohort A). As for Figure 3, the heatmap is limited to the 17% most up- or down-
910 regulated proteins (by fold change) of those with a significant association.

911

912 **Figure 3 figure supplement 2 – Permutation analysis to estimate the null distribution.**

913 Histogram showing the distribution of the number of associations declared significant (FDR
914 5%) after random permutation of class labels (100,000 replications). **a)** the COVID-19 +ve
915 versus -ve differential abundance analysis. **b)** the COVID-19 severity differential abundance
916 analysis. The vertical red line denotes the number of proteins we found significant in the
917 analysis with the true sample labels.

918

919 **Figure 3 figure supplement 3 – Sensitivity analyses adjusting for diabetes status and
920 cause of ESKD.**

921 As sensitivity analyses, the COVID-19 positive versus negative differential abundance
922 regressions were repeated adding diabetes status (a-b) and cause of ESKD (c-d) as
923 additional covariates. The basic model included age, sex and ethnicity as covariates. Each
924 point represents a protein. A comparison of $-\log_{10}$ p-values and effect sizes are shown for
925 all 436 proteins. r indicates Pearson's correlation coefficient.

926

927 **Figure 3 figure supplement 4 – Sensitivity analysis adjusting for time since last
928 haemodialysis.**

929 Comparison of results obtained with and without adding time since last haemodialysis as an
930 additional covariate to the regression models. **a-b)** COVID-19 positive versus negative
931 differential expression analysis. **c-d)** Severity analysis. Each point represents a protein. r
932 indicates Pearson's correlation coefficient.

933

934 **Figure 4 – Validation.**

935 **a)** Overlap between the significant associations in the differential abundance analysis
936 between ESKD patients with and without COVID-19 in subcohorts A and B. 5% FDR was
937 used as the significance threshold in both analyses.

938 **b)** Comparison of estimated effect sizes for all 436 proteins in the differential abundance
939 analyses (COVID-19 positive versus negative) in subcohort A and B. Each point represents
940 a protein. Pearson's r is shown.

941 Differential abundance analyses were performed using linear mixed models. Subcohort A
942 analysis (plasma samples): 256 samples from 55 COVID-19 patients versus 51 non-infected
943 patient samples (single time-point). Subcohort B (serum samples): 52 samples from 55
944 COVID-19 patients and 11 non-infected patient samples (single time-point).

945

946 **Figure 4 figure supplement 1– Comparison with the report of Filbin *et al.* [16]**

947 Comparison of \log_2 fold change for COVID-19 positive versus negative ESKD patients in our
948 study versus COVID-19 positive versus negative respiratory distress patients in the report by
949 Filbin *et al.* [16]. Colours indicate whether a protein was significantly differentially abundant
950 in each study. Pearson's r is shown.

951

952 **Figure 5 - Selected proteins strongly associated with COVID-19 severity.**

953 Violin plots showing distribution of plasma protein levels according to COVID-19 status at the
954 time of blood draw. Boxplots indicate plasma median and interquartile range. $n=256$ samples from
955 55 COVID-19 patients and 51 samples from non-infected patients. WHO severity indicates
956 the clinical severity score of the patient at the time the sample was taken. Mild $n=135$
957 samples; moderate $n=77$ samples; severe $n=29$ samples; critical $n=15$ samples. Upper
958 panel: monocyte chemokines. Middle panel: markers of epithelial injury. Lower panel: 2
959 neutrophil proteases, and IL6.

960

961 **Figure 6 – comparison of proteins differentially expressed in COVID-19 with those
962 associated with clinical severity.**

963 a) Overlap between the proteins significantly differentially expressed in COVID-19 (n=256
964 COVID-19 samples and 51 non-infected samples) versus those associated with severity
965 (within cases analysis, n=256 samples) (subcohort A). 5% FDR was used as the significant
966 cut-off in both analyses.

967 b) Comparison of effect sizes for each protein in the COVID-19 positive versus negative
968 analysis (x-axis) and severity analysis (y-axis). Each point represents a protein. Pearson's r
969 is shown.

970 c) Examples of proteins specifically associated with severity but not significantly differentially
971 abundant in the comparison of all cases versus controls. Violin plots showing distribution of
972 plasma protein levels according to COVID-19 status at the time of blood draw. Boxplots
973 indicate median and interquartile range. n=256 samples from 55 COVID-19 patients and 51
974 samples from non-infected patients. WHO severity indicates the clinical severity score of the
975 patient at the time the sample was taken. Mild n=135 samples; moderate n=77 samples;
976 severe n=29 samples; critical n= 15 samples.

977

978 **Figure 7 – Prediction of severe COVID-19 and death.**

979 a) The 12 most important proteins for predicting overall clinical course (defined by peak
980 COVID-19 WHO severity) using Random Forests supervised learning. If a variable is
981 important for prediction, it is likely to appear in many decision trees (number of trees) and be
982 close to the root node (i.e. have a low minimal depth). The mean minimal depth across all
983 trees (white box) was used as the primary feature selection metric.

984 b) Proteins that are significant predictors of death (Benjamini-Hochberg adjusted p <0.05).
985 n=256 samples from 55 COVID-19 positive patients, of whom 9 died. Risk coefficient
986 estimates are from a joint model. Bars indicate 95% confidence intervals. For proteins with a
987 positive risk coefficient, a higher concentration corresponds to a high risk of death, and vice
988 versa for proteins with negative coefficients.

989

990 **Figure 7 figure supplement 1 – proteins associated with risk of death: correlation to 991 clinical severity and clinical laboratory measurements.**

992 Proteins significantly associated with risk of death (5% FDR) are shown. The estimated
993 effect size from the linear mixed model testing association with severity are also shown.
994 Correlations between protein levels and contemporaneous clinical laboratory marker values
995 were calculated using rcorr [55] for each of the proteins significant (5% FDR) in the joint
996 model. The rows and columns of the clinical marker correlation matrix are ordered by
997 hierarchical clustering.

998

999 **Figure 8 – Associations of clinical laboratory markers with plasma proteins.**

1000 Proteins that are positively (red) or negatively (blue) associated with clinical laboratory
1001 parameters (5% FDR). P-values from differential abundance analysis using linear mixed
1002 models after Benjamini-Hochberg adjustment. Dark-grey = non-significant. Two associations
1003 were found for d-dimer (not shown- see **Supplementary File 1g**).

1004

1005 **Figure 9 – Modelling of temporal protein trajectories.**

1006 The top 18 proteins displaying the most significantly (5% FDR) different longitudinal
1007 trajectories between patients with a mild or moderate (n= 28) versus severe or critical (n=
1008 27) overall clinical course (defined by peak WHO severity). Means and 95% confidence
1009 intervals for each group, predicted using linear mixed models (**Methods**), are plotted. The
1010 remainder of significant proteins are shown in **Figure 9 figure supplement 1**. Individual
1011 data points are shown in **Figure 9 figure supplement 2**.

1012

1013 **Figure 9 figure supplement 1– display of modelled temporal trajectories for other
1014 proteins with a significant time x severity interaction.** Proteins significant at 5% FDR but
1015 not shown in Figure 9 are displayed here.

1016

1017 **Figure 9 figure supplement 2– raw data points for modelling of temporal protein**
1018 **trajectories.** The 8 most significant proteins from Figure 9 are displayed.
1019
1020
1021
1022

1023

	COVID-19 positive ESKD patients (n=55)			ESKD controls (n=51)
	Overall	Patients with peak severity mild or moderate (n=28)	Patient with peak severity severe or critical (n=27)	
Age				
Median (Q1-Q3)	72.2 62.5-77.3	73.4 65.5-76.4	68.5 61.8-78.8	70.1 62.2-75.1
Sex				
M	39 (70.9%)	18 (64.3%)	21 (77.8%)	36 (70.6%)
F	16 (29.1%)	10 (35.7%)	6 (22.2%)	15 (29.4%)
Ethnicity				
White	16 (29.1%)	5 (17.9%)	11 (40.7%)	13 (25.5%)
Black	8 (14.5%)	5 (17.9%)	3 (11.1%)	8 (15.7%)
South Asian	18 (32.7%)	10 (35.7%)	8 (29.6%)	20 (39.2%)
Asian (other)	4 (7.3%)	1 (3.6%)	3 (11.1%)	3 (5.9%)
Other	9 (16.4%)	7 (25.0%)	2 (7.4%)	7 (13.7%)
Diabetes	34 (61.8%) *	16 (57.1%)	18 (66.7%)	24 (47.1%) *
Current Smoker	1 (1.8%)	1 (3.6%)	0	0
ESKD Cause				
DN	29 (52.7%)	14 (50.0%)	15 (55.6%)	20 (39.2%)
Genetic	1 (1.8%)	1 (3.6%)	0	1 (2.0%)
GN	3 (5.5%)	1 (3.6%)	2 (7.4%)	9 (17.6%)
HTN/Vascular	5 (9.1%)	3 (5.5%)	2 (7.4%)	7 (13.7%)
Other	8 (14.5%)	5 (17.9%)	3 (11.1%)	4 (7.8%)
Unknown	9 (16.4%)	4 (14.3%)	5 (18.5%)	10 (19.6%)
Hospitalisation due to COVID-19†	33 (60%)	6 (21.4%)	27 (100%)	N/A
Fatal COVID-19	9 (16.3%)	0 (0%)	9 (33.3%)	N/A

1024

1025

Table 1 – Characteristics of subcohort A.

1026

GN = Glomerulonephritis. HTN = Hypertension. IQR = inter-quartile range. 'South Asian' represents individuals with Indian, Pakistani or Bangladeshi ancestry. Subsets defined according to peak WHO severity over the course of the illness. N/A = not applicable.

1027

1028

1029

*One patient had type 1 diabetes, the remainder type 2.

1030

1031

	COVID-19 positive ESKD patients (n=46)	COVID-19 negative ESKD controls (n=11)*
Age		
Median (Q1-Q3)	64.3 60.3-73.0	71.6 (61.7-73.9)
Sex		
M	32 (69.6%)	8 (72.3%)
F	14 (30.4%)	3 (27.3%)
Ethnicity		
White	11 (23.9%)	3 (27.3%)
Black	8 (17.4%)	3 (27.3%)
South Asian	12 (26.1%)	3 (27.3%)
Asian (other)	7 (15.2%)	0
Other	8 (17.4%)	2 (18.2%)
Diabetes	29 (63.0%)	6 (54.5%)
Current Smoker	2 (4.3%)	0 (%)
ESKD Cause		
DN	19 (41.3%)	5 (45.5%)
Genetic	1 (2.2%)	0
GN	7 (15.2%)	1 (9.1%)
HTN/Vascular	3 (6.5%)	1 (9.1%)
Other	3 (6.5%)	2 (18.2%)
Unknown	13 (28.3%)	2 (18.2%)
Hospitalisation due to COVID-19	41 (89.1%)	N/A
Severe or critical COVID-19	33 (71.7%)	N/A
Fatal COVID-19	9 (19.6%)	N/A

1032

1033

Table 2 – Characteristics of subcohort B.

1034

GN = Glomerulonephritis. HTN = Hypertension. IQR = inter-quartile range. ‘South Asian’ represents individuals with Indian, Pakistani or Bangladeshi ancestry. Subsets defined according to peak WHO severity over the course of the illness. N/A = not applicable. *These 11 controls are a subset of the control patients used in subcohort A.

1035

1036

1037

1038

1039

1040 **Supplementary File 1 table legends.**

1041

1042 **Supplementary File 1a. Protein Annotation.**

1043 List of the 436 proteins measured. GeneID = gene symbol of the gene encoding the protein (used as
1044 the main identifier in the manuscript); UniProt = UniProt ID; Olink Assay Name = protein id used by
1045 Olink; Protein Name = full protein name; Panel name = the name of the 92 protein multiplex Olink
1046 panel on which the protein was measured.

1047

1048 **Supplementary File 1b. Enrichment of Reactome terms for the entire set of proteins measured.**

1049 The results of enrichment testing for genes corresponding to all 436 measured proteins against the
1050 background of the genome. The analysis was performed against the Reactome pathways using
1051 string-db. The list of Reactome terms is ordered by the number of proteins associated with the term.

1052

1053 **Supplementary File 1c. Differential abundance analysis for COVID-19 positive vs negative
1054 ESKD patients in subcohort A and B.**

1055 Summary statistics for all 436 proteins are shown. Pvalue = nominal p-value from linear mixed model.
1056 Adjusted Pvalue = p-values after Benjamini-Hochberg correction. Fold change = estimated fold
1057 change from regression coefficient. Proteins are ordered based on results in subcohort A: first by
1058 whether they are significant or not (at 5% FDR), then by fold change (from positive to negative). Note
1059 the associations are not ordered by p-value so strong associations do not necessarily appear at the
1060 top of the table. Significant adjusted p-values are coloured in green and non-significant in grey.
1061 Estimated fold changes are coloured in a gradient from red to blue for up or downregulated in COVID-
1062 19 +ve versus -ve, respectively.

1063 Sample size for subcohort A: n= 256 plasma samples from 55 COVID-19 positive ESKD patients,
1064 versus n= 51 ESKD controls (1 sample per control patient).

1065 Sample size for subcohort B: 52 samples from 55 COVID-19 patients and 11 non-infected patient
1066 samples (single time-point).

1067

1068 **Supplementary File 1d Associations of proteins and COVID-19 severity (subcohort A).**

1069 Summary statistics for all 436 proteins are shown. Pvalue = nominal p-value from linear mixed model.
1070 Adjusted Pvalue = p-values after Benjamini-Hochberg correction. Fold change = estimated fold
1071 change from regression coefficient. Proteins are ordered first by whether they are significant or not (at
1072 5% FDR), then by linear gradient (effect size) from positive to negative. Note the associations are not
1073 ordered by p-value so strong associations do not necessarily appear at the top of the table.

1074

1075 **Supplementary File 1e. Predictors of clinical course from Random Forests.**

1076 Importance metrics for each protein for prediction according to a random forest model trained to
1077 predict current or future severe/critical disease using the first sample of each patient. Proteins are
1078 ordered by mean minimal depth across all trees – this was used as the primary importance metric.

1079

1080 **Supplementary File 1f. Proteomic predictors of fatal COVID-19.**

1081 Summary statistics from joint models for fatal disease. Results for all 436 proteins are shown. “Is
1082 significant” indicates significance (green) or not (grey) at 5% FDR. The association coefficient for
1083 each protein indicates the direction and magnitude of the estimated log relative risk for death (red
1084 indicates higher protein levels increase risk of death, blue the opposite). 95% confidence intervals are
1085 plotted.

1086

1087 **Supplementary File 1g. Associations of proteins and clinical laboratory measurements.**

1088 Clinical variable = clinical lab tests: white cell count, lymphocyte count, neutrophil count, monocyte
1089 count, C-reactive protein, ferritin, d-dimer, troponin.

1090

1091 **Supplementary File 1h. Longitudinal proteomic profiling with linear mixed models.**

1092 Summary statistics from the linear mixed models used to identify proteins with differential temporal
1093 trajectories between mild/moderate (n=28) and severe/critical COVID-19 patients (n=27). Summary
1094 statistics for all 436 proteins are shown.

1095

1096 Pvalue = nominal p-value from linear mixed model for the interaction term between time from
1097 symptom onset (days) and overall WHO severity (as a binary variable: mild-moderate or severe-
1098 critical).

1099
1100 Adjusted Pvalue = p-values after Benjamini-Hochberg correction. "Is significant" indicates significance
1101 (green) or not (grey) at 5% FDR.

1102
1103 **Supplementary File 1i. Comparison to other proteomic studies of COVID-19 positive vs**
1104 **negative patients.**

1105 Proteins that were differentially abundant in COVID-19 +ve vs -ve patients in our data are listed (5%
1106 FDR). TRUE indicates that the protein was reported as differentially abundant in the relevant previous
1107 proteomic study. The final column summarises whether the association was previously reported in
1108 any of the 4 studies. We have not harmonised significance thresholds between studies: we simply
1109 report whether the authors declared the protein significant by the threshold of their study.

1110
1111 **Supplementary File 1j. Comparison to other proteomic studies of COVID-19 severity.**
1112 Proteins that were associated with severity in our data are listed (5% FDR). TRUE indicates that the
1113 protein was reported as associated with severity in the relevant previous proteomic study. The final
1114 column summarises whether the association was previously reported in any 1 or more of the 4
1115 studies. We have not harmonised significance thresholds between studies: we simply report whether
1116 the authors declared the protein significant by the threshold of their study.

1117
1118 Results are shown for all 436 proteins against all 8 lab measurements.

1119
1120 Adjusted p-value = p-value from linear mixed model after Benjamini-Hochberg correction.

1121
1122 Gradient indicates effect size and direction. A positive gradient (red) indicates higher concentrations
1123 of proteins are associated with higher clinical laboratory measurements. "Is significant" indicates
1124 significance (green) or not (grey) at 5% FDR.

1125
1126 Contemporaneous clinical laboratory tests were not available for all plasma samples. The proportion
1127 of samples for which contemporaneous lab tests were available were: white cell count 66%,
1128 neutrophils 66%, monocytes 66%, lymphocytes 66%, CRP 64%, ferritin 36%, troponin 35%, d-dimer
1129 30%.

1130
1131 **Supplementary File 1k. Per protein correlations between plasma and serum levels derived**
1132 **from the same blood sample in 11 COVID-19 negative ESKD patients.**

1133 Plasma and serum were taken from 11 non-infected ESKD patients that were measured in both
1134 subcohort A (plasma) and B (serum). Pearson's r was calculated for the 11 paired measurements for
1135 each protein. Proteins are ordered by r value; this column is coloured from red to blue for positive and
1136 negative r values, respectively. 95% confidence intervals are reported. We also report the variance of
1137 the NPX levels for each protein in plasma and in serum.

1138
1139

1140 References

- 1141 1. Horby, P. *et al.* Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary
1142 Report. *N. Engl. J. Med.* **0**, NEJMoa2021436 (2020) doi:10.1056/NEJMoa2021436.
- 1143 2. Gordon, A. C. *et al.* Interleukin-6 Receptor Antagonists in Critically Ill Patients with
1144 Covid-19 - Preliminary report. *medRxiv* (2021) doi:10.1101/2021.01.07.21249390.
- 1145 3. Suhre, K., McCarthy, M. I. & Schwenk, J. M. Genetics meets proteomics: perspectives
1146 for large population-based studies. *Nat. Rev. Genet.* (2020) doi:10.1038/s41576-020-
1147 0268-2.
- 1148 4. Williamson, E. J. *et al.* Factors associated with COVID-19-related death using
1149 OpenSAFELY. *Nature* **584**, 430–436 (2020) doi:10.1038/s41586-020-2521-4.
- 1150 5. Docherty, A. B. *et al.* Features of 16,749 hospitalised UK patients with COVID-19
1151 using the ISARIC WHO Clinical Characterisation Protocol. *medRxiv*
1152 2020.04.23.20076042 (2020) doi:10.1101/2020.04.23.20076042.
- 1153 6. Corbett, R. W. *et al.* Epidemiology of COVID-19 in an Urban Dialysis Center. *J. Am.*
1154 *Soc. Nephrol.* **31**, 1815–1823 (2020) doi:10.1681/ASN.2020040534.
- 1155 7. Ng, J. H. *et al.* Outcomes of patients with end-stage kidney disease hospitalized with
1156 COVID-19. *Kidney Int.* (2020) doi:10.1016/j.kint.2020.07.030.
- 1157 8. Valeri, A. M. *et al.* Presentation and outcomes of patients with ESKD and COVID-19.
1158 *J. Am. Soc. Nephrol.* **31**, 1409–1415 (2020) doi:10.1681/ASN.2020040470.
- 1159 9. Hastie T, Tibshirani R, F. J. High-Dimensional Problems: $p \gg N$. in *The Elements of*
1160 *Statistical Learning* 649–698 (Springer Series in Statistics, 2001).
- 1161 10. Ibrahim, J. G., Chu, H. & Chen, L. M. Basic concepts and methods for joint models of
1162 longitudinal and survival data. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **28**, 2796–
1163 2801 (2010) doi:10.1200/JCO.2009.25.0654.
- 1164 11. Rizopoulos, D. JM: An R package for the joint modelling of longitudinal and time-to-
1165 event data. *J. Stat. Softw.* **35**, 1–33 (2010) doi:10.18637/jss.v035.i09.
- 1166 12. Guan, W. *et al.* Clinical characteristics of coronavirus disease 2019 in China. *N. Engl.*
1167 *J. Med.* **382**, 1708–1720 (2020) doi:10.1056/NEJMoa2002032.
- 1168 13. Shen, B. *et al.* Proteomic and Metabolomic Characterization of COVID-19 Patient
1169 Sera. *Cell* **182**, 59-72.e15 (2020) doi:10.1016/j.cell.2020.05.032.
- 1170 14. Lucas, C. *et al.* Longitudinal analyses reveal immunological misfiring in severe
1171 COVID-19. *Nature* **584**, 463–469 (2020) doi:10.1038/s41586-020-2588-y.
- 1172 15. Arunachalam, P. S. *et al.* Systems biological assessment of immunity to mild versus
1173 severe COVID-19 infection in humans. *Science (80-.).* **6261**, 1–18 (2020)
1174 doi:10.1126/science.abc6261.
- 1175 16. Filbin, M. R. *et al.* Plasma proteomics reveals tissue-specific cell death and mediators
1176 of cell-cell interactions in severe COVID-19 patients. *bioRxiv* 2020.11.02.365536
1177 (2020) doi:10.1101/2020.11.02.365536.
- 1178 17. COVID-19 Data. *The Renal Association* <https://renal.org/health-professionals/covid-19/covid-19-data> (2020).
1179
- 1180 18. Scottish Renal Registry COVID-19 report. *Public Health Scotland*
1181 <https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/scottish-renal-registry-covid-19-report/> (2020).
1182

- 1183 19. Eiselt, J. *et al.* Previous Vaccination and Age are More Important Predictors of
1184 Immune Response to Influenza Vaccine than Inflammation and Iron Status in Dialysis
1185 Patients. *Kidney Blood Press. Res.* **41**, 139–147 (2016) doi:10.1159/000443416.
- 1186 20. Girndt, M., Sester, U., Sester, M., Kaul, H. & Köhler, H. Impaired cellular immune
1187 function in patients with end-stage renal failure. *Nephrology, dialysis,*
1188 *transplantation*: official publication of the European Dialysis and Transplant
1189 Association - European Renal Association vol. 14 2807–2810 (1999)
1190 doi:10.1093/ndt/14.12.2807.
- 1191 21. Sarnak, M. J. & Jaber, B. L. Mortality caused by sepsis in patients with end-stage
1192 renal disease compared with the general population. *Kidney Int.* **58**, 1758–1764
1193 (2000) doi:10.1111/j.1523-1755.2000.00337.x.
- 1194 22. Alexiewicz, J. M., Smogorzewski, M., Fadda, G. Z. & Massry, S. G. Impaired
1195 phagocytosis in dialysis patients: studies on mechanisms. *Am. J. Nephrol.* **11**, 102–
1196 111 (1991) doi:10.1159/000168284.
- 1197 23. Massry, S. & Smogorzewski, M. Dysfunction of polymorphonuclear leukocytes in
1198 uremia: role of parathyroid hormone. *Kidney Int. Suppl.* **78**, S195-6 (2001)
1199 doi:10.1046/j.1523-1755.2001.59780195.x.
- 1200 24. Girndt, M., Sester, M., Sester, U., Kaul, H. & Köhler, H. Molecular aspects of T- and
1201 B-cell function in uremia. *Kidney Int. Suppl.* **78**, S206-11 (2001) doi:10.1046/j.1523-
1202 1755.2001.59780206.x.
- 1203 25. Meier, P., Dayer, E., Blanc, E. & Wauters, J.-P. Early T cell activation correlates with
1204 expression of apoptosis markers in patients with end-stage renal disease. *J. Am.*
1205 *Soc. Nephrol.* **13**, 204–212 (2002).
- 1206 26. Betjes, M. G. H. Immune cell dysfunction and inflammation in end-stage renal
1207 disease. *Nat. Rev. Nephrol.* **9**, 255–265 (2013) doi:10.1038/nrneph.2013.44.
- 1208 27. Boattini, M. *et al.* Influenza and respiratory syncytial virus infections in the oldest-old
1209 continent. *Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol.* **39**,
1210 2085–2090 (2020) doi:10.1007/s10096-020-03959-9.
- 1211 28. Prasad, N. *et al.* Respiratory Syncytial Virus–Associated Hospitalizations Among
1212 Adults With Chronic Medical Conditions. *Clin. Infect. Dis.* (2020)
1213 doi:10.1093/cid/ciaa730.
- 1214 29. Usvyat, L. A. *et al.* Seasonal variations in mortality, clinical, and laboratory parameters
1215 in hemodialysis patients: a 5-year cohort study. *Clin. J. Am. Soc. Nephrol.* **7**, 108–
1216 115 (2012) doi:10.2215/CJN.03880411.
- 1217 30. Carrero, J. J. & Stenvinkel, P. Inflammation in end-stage renal disease--what have we
1218 learned in 10 years? *Semin. Dial.* **23**, 498–509 (2010) doi:10.1111/j.1525-
1219 139X.2010.00784.x.
- 1220 31. Naseeb, U. *et al.* Complementary LC-MS/MS Proteomic Analysis of Uremic Plasma
1221 Proteins. *J. Coll. Physicians Surg. Pak.* **25**, 606–609 (2015).
- 1222 32. Christensson, A. *et al.* The Impact of the Glomerular Filtration Rate on the Human
1223 Plasma Proteome. *Proteomics. Clin. Appl.* **12**, e1700067 (2018)
1224 doi:10.1002/prca.201700067.
- 1225 33. Lind, L. *et al.* Longitudinal effects of aging on plasma proteins levels in older adults -
1226 associations with kidney function and hemoglobin levels. *PLoS One* **14**, e0212060
1227 (2019) doi:10.1371/journal.pone.0212060.


- 1228 34. Wu, C. *et al.* Risk Factors Associated With Acute Respiratory Distress Syndrome and
1229 Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.
1230 *JAMA Intern. Med.* **180**, 934–943 (2020) doi:10.1001/jamainternmed.2020.0994.
- 1231 35. Li, X. *et al.* Risk factors for severity and mortality in adult COVID-19 inpatients in
1232 Wuhan. *J. Allergy Clin. Immunol.* **146**, 110–118 (2020) doi:10.1016/j.jaci.2020.04.006.
- 1233 36. Furlow, B. COVACTA trial raises questions about tocilizumab's benefit in COVID-19.
1234 *Lancet Rheumatol.* **2**, e592 (2020) doi:10.1016/S2665-9913(20)30313-1.
- 1235 37. Gupta, R. K. *et al.* Development and validation of the ISARIC 4C Deterioration model
1236 for adults hospitalised with COVID-19: a prospective cohort study. *Lancet. Respir.*
1237 *Med.* (2021) doi:10.1016/S2213-2600(20)30559-2.
- 1238 38. Schutyser, E., Struyf, S. & Van Damme, J. The CC chemokine CCL20 and its
1239 receptor CCR6. *Cytokine Growth Factor Rev.* **14**, 409–426 (2003) doi:10.1016/s1359-
1240 6101(03)00049-2.
- 1241 39. Saha, S. K. *et al.* KRT19 directly interacts with β -catenin/RAC1 complex to regulate
1242 NUMB-dependent NOTCH signaling pathway and breast cancer properties.
1243 *Oncogene* **36**, 332–349 (2017) doi:10.1038/onc.2016.221.
- 1244 40. Maecker, H. *et al.* TWEAK attenuates the transition from innate to adaptive immunity.
1245 *Cell* **123**, 931–944 (2005) doi:10.1016/j.cell.2005.09.022.
- 1246 41. Burkly, L. C., Michaelson, J. S., Hahm, K., Jakubowski, A. & Zheng, T. S. TWEAKing
1247 tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in
1248 health and disease. *Cytokine* **40**, 1–16 (2007) doi:10.1016/j.cyto.2007.09.007.
- 1249 42. Henning, R. J., Bourgeois, M. & Harbison, R. D. Poly(ADP-ribose) Polymerase
1250 (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular
1251 Disorders. *Cardiovasc. Toxicol.* **18**, 493–506 (2018) doi:10.1007/s12012-018-9462-2.
- 1252 43. Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H. & Poirier, G. G. PARP
1253 inhibition: PARP1 and beyond. *Nat. Rev. Cancer* **10**, 293–301 (2010)
1254 doi:10.1038/nrc2812.
- 1255 44. Corren, J. New Targeted Therapies for Uncontrolled Asthma. *J. allergy Clin. Immunol.*
1256 *Pract.* **7**, 1394–1403 (2019) doi:10.1016/j.jaip.2019.03.022.
- 1257 45. Galijasevic, S. The development of myeloperoxidase inhibitors. *Bioorg. Med. Chem.*
1258 *Lett.* **29**, 1–7 (2019) doi:10.1016/j.bmcl.2018.11.031.
- 1259 46. Vergunst, C. E. *et al.* Modulation of CCR2 in rheumatoid arthritis: a double-blind,
1260 randomized, placebo-controlled clinical trial. *Arthritis Rheum.* **58**, 1931–1939 (2008)
1261 doi:10.1002/art.23591.
- 1262 47. Haringman, J. J. *et al.* A randomized controlled trial with an anti-CCL2 (anti-monocyte
1263 chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis.
1264 *Arthritis Rheum.* **54**, 2387–2392 (2006) doi:10.1002/art.21975.
- 1265 48. Rodriguez, L. *et al.* Systems-Level Immunomonitoring from Acute to Recovery Phase
1266 of Severe COVID-19. *Cell reports. Med.* **1**, 100078 (2020)
1267 doi:10.1016/j.xcrm.2020.100078.
- 1268 49. Uhlen, M. *et al.* Tissue-based map of the human proteome. *Science (80-.).* **347**,
1269 1260419–1260419 (2015) doi:10.1126/science.1260419.
- 1270 50. Szklarczyk, D. *et al.* STRING v11: Protein-protein association networks with increased
1271 coverage, supporting functional discovery in genome-wide experimental datasets.
1272 *Nucleic Acids Res.* **47**, D607–D613 (2019) doi:10.1093/nar/gky1131.

- 1273 51. Gandolfo, L. C. & Speed, T. P. RLE plots: Visualizing unwanted variation in high
1274 dimensional data. *PLoS One* **13**, 1–9 (2018) doi:10.1371/journal.pone.0191629.
- 1275 52. Kuhn, M. Building predictive models in R using the caret package. *J. Stat. Softw.* **28**,
1276 1–26 (2008) doi:10.18637/jss.v028.i05.
- 1277 53. Bates, D., Mächler, M., Bolker, B. & Walker, S. Fitting Linear Mixed-Effects Models
1278 Using lme4. *J. Stat. Softw.* **67**, (2015) doi:10.18637/jss.v067.i01.
- 1279 54. Kuznetsova, A., Brockhoff, P. B. & Christensen, R. H. B. lmerTest Package: Tests in
1280 Linear Mixed Effects Models. *J. Stat. Softw.* **82**, (2017) doi:10.18637/jss.v082.i13.
- 1281 55. Bakdash, J. Z. & Marusich, L. R. Repeated measures correlation. *Front. Psychol.* **8**,
1282 1–13 (2017) doi:10.3389/fpsyg.2017.00456.
- 1283 56. Leo, B. Random forests. *Mach. Learn.* **45**, 5–32 (2001)
1284 doi:10.1023/A:1010933404324.
- 1285 57. Perperoglou, A., Sauerbrei, W., Abrahamowicz, M. & Schmid, M. A review of spline
1286 function procedures in R. *BMC Med. Res. Methodol.* **19**, 1–16 (2019)
1287 doi:10.1186/s12874-019-0666-3.
- 1288

Figure 1

medRxiv preprint doi: <https://doi.org/10.1101/2020.11.05.20223289>; this version posted February 15, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).

a



b




Figure 2

COVID-19 Status ● Negative ● Positive




Figure 3





Figure 4

a

Subcohort A
COVID-19
+ve vs -ve
(plasma)

Subcohort B
COVID-19
+ve vs -ve
(serum)



b

Significance ● None ● Serum only ● Plasma only ● Both




Figure 5







Figure 6**a****b****c**

Figure 7











Figure 8**Lymphocyte Count****C-Reactive Protein****Ferritin****Neutrophil Count****White Cell Count****Monocyte Count**

Figure 9




Figure 1 figure supplement 1








Figure 2 figure supplement 1

COVID-19 WHO Severity

● Negative ● Mild ● Moderate ● Severe ● Critical

a

Severity at time of sampling



b

Overall clinical course




Figure 2 figure supplement 2




Figure 3 figure supplement 1





Figure 3 figure supplement 2

a

COVID-19 +ve vs -ve
differential abundance analysis



b

COVID-19 severity
differential abundance analysis




Figure 3 figure supplement 3









Figure 3 figure supplement 4

COVID-19 +ve vs -ve differential abundance analysis



COVID-19 Severity differential abundance analysis





Figure 4 figure supplement 1

Significance ● None ● Differential Abundance Analysis ● *Filbin et al.* ● Both




Figure 7 figure supplement 1




Figure 9 figure supplement 1




Figure 9 figure supplement 2

